IFNA1 and systemic lupus erythematosus: Hydroxychloroquine shows multiple protective effects (77), reducing IFN-α production, aortic stiffness, correcting lipoprotein profile, improving glycemic control, as well as reducing the risk of all thrombo-vascular events in SLE patients.